IP Library › Granted Patent US 10,329,333
Granted Patent B2
US 10,329,333 · App. 15/785,529 · Granted Jun 25, 2019

Controlled gene expression methods

Inventors: Gerd Blobel (Bala Cynwyd, PA); Wulan Deng (Berkeley, CA)
Assignee: The Children's Hospital of Philadelphia
C07K14/4702A61K48/00C07K14/47C12N15/63C07K2319/81
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,329,333
App. No.
15/785,529
Granted
Jun 25, 2019
Kind
B2
Abstract

Methods and compositions for controlling gene expression are disclosed.

Claims (15)

1. A method of inhibiting a disease or disorder in a subject comprising administering to said subject a composition comprising i) a nucleic acid molecule encoding a polypeptide comprising a DNA binding domain and a looping factor, wherein said looping factor is a fragment of LIM domain binding 1 (Ldb1), and ii) at least one pharmaceutically acceptable carrier,

wherein said fragment of Ldb1 comprises an amino acid sequence having at least 90% identity with amino acids 1 to 200 of SEQ ID NO: 1.

2. The method of claim 1 , wherein said disease or disorder is sickle cell anemia or beta-thalassemia and wherein said DNA binding domain specifically binds a target sequence in a globin promoter.

3. The method of claim 2 , wherein said DNA binding domain specifically binds a target sequence in the fetal (gamma) gene promoter.

4. The method of claim 1 , wherein said DNA binding domain and said looping factor are linked through a covalent bond or an amino acid linker.

5. The method of claim 1 , wherein said Ldb1 is human.

6. The method of claim 1 , wherein said fragment of Ldb1 comprises amino acids 1 to about 200 of SEQ ID NO: 1.

7. The method of claim 1 , wherein said DNA binding domain comprises a zinc finger protein or a transcription activator-like effector protein.

8. The method of claim 1 , wherein said DNA binding domain specifically binds a target sequence in the promoter of a gene aberrantly expressed in said disease or disorder.

9. The method of claim 8 , wherein said promoter is a globin promoter.

10. The method of claim 1 , wherein said looping factor consists of amino acids 1 to 200 of SEQ ID NO: 1.

11. The method of claim 1 , wherein said looping factor is an N-terminal fragment of Ldb1, wherein said N-terminal fragment of Ldb1 comprises amino acids 1 to 200 of SEQ ID NO: 1.

12. The method of claim 1 , wherein said method comprises administering a first and second nucleic acid molecule,

wherein said first nucleic acid molecule encodes a first polypeptide comprising a first DNA binding domain and a first looping factor, wherein said first looping factor is LIM domain binding 1 (Ldb1) or a fragment thereof, and wherein said first DNA binding domain specifically binds to a target sequence in the promoter of a gene of interest, and

wherein said second nucleic acid molecule encodes a second polypeptide comprising a second DNA binding domain and a second looping factor, wherein said second looping factor is LIM domain binding 1 (Ldb1) or a fragment thereof, and wherein said second DNA binding domain specifically binds to a target sequence in the locus control region of said gene of interest.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 6, 2019
From: BLOBEL, GERD; DENG, WULAN
To: THE CHILDREN'S HOSPITAL OF PHILADELPHIA
Reel/Frame 049089/0397 →
Continuity (3)
Division 14405932
Provisional Application 61656961 · Jun 7, 2012
Related Publication 20180051059A1 · Feb 22, 2018